C5a receptor antagonists - G2 Therapies/Novo Nordisk

Drug Profile

C5a receptor antagonists - G2 Therapies/Novo Nordisk

Alternative Names: Neutrazumab

Latest Information Update: 19 Jan 2011

Price : $50

At a glance

  • Originator G2 Therapies
  • Developer G2 Therapies; Novo Nordisk
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 23 Aug 2005 Preclinical trials in Rheumatoid arthritis in Australia (unspecified route)
  • 23 Aug 2005 This programme is available for licensing (http://www.g2therapies.com.au)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top